title: Evolution of Ig- and T-cell receptor gene configuration in a Ph1+ hybrid leukemia patient.
abstract: In a longitudinal study of a 32-year-old male with Ph1+ hybrid leukemia we have followed the immunophenotype and configuration of Ig- and TCR genes during the course of different chemotherapy regimens directed first against the myeloid and later against the lymphoid components of the disease. We identified changes in all parameters, interpretable as an evolution of the malignant clone resulting in a leukemic switch towards a more lymphoid character. Thus, while the expression of the myeloid antigens CD13 and CD33 decreased, that of CD10 (CALLA) and CD20 (B1) increased. Moreover, while the configuration of the Ig heavy and light chain lambda genes remained constant during the whole period of treatment, that of the Ig light chain kappa gene and TCR beta gene displayed extensive rearrangements after initiation of ALL therapy. Since this patient represents a de novo acute leukemia as evaluated by location of the translocation-breakpoint on chromosome 22, our data clearly indicate that Ig- and TCR gene rearrangements might prove a valuable addition in monitoring Ph1+ hybrid leukemias, providing guidelines for optimizing chemotherapy.
authors.affiliation: Institute of Medical Microbiology, University of Aarhus, Denmark.
authors.forename: A W
authors.initials: AW
authors.lastname: Jensen
authors.forename: P
authors.initials: P
authors.lastname: Hokland
authors.forename: J S
authors.initials: JS
authors.lastname: Kristensen
authors.forename: J
authors.initials: J
authors.lastname: Justesen
authors.forename: M
authors.initials: M
authors.lastname: Hokland
mesh_terms: D000328:Adult; D002892:Chromosomes, Human, Pair 22; D015328:Gene Rearrangement, B-Lymphocyte, Light Chain / Q000235:genetics; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / Q000235:genetics; D005803:Genes, Immunoglobulin / Q000235:genetics*; D006801:Humans; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*
chemical_list: D011948:Receptors, Antigen, T-Cell